Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.
J Virol
; 87(13): 7747-53, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23658441
ABSTRACT
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and â¼3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Biespecíficos
/
Dengue
/
Vírus da Dengue
/
Terapia de Alvo Molecular
/
Anticorpos Monoclonais
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Virol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos